JP2015501784A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501784A5
JP2015501784A5 JP2014540115A JP2014540115A JP2015501784A5 JP 2015501784 A5 JP2015501784 A5 JP 2015501784A5 JP 2014540115 A JP2014540115 A JP 2014540115A JP 2014540115 A JP2014540115 A JP 2014540115A JP 2015501784 A5 JP2015501784 A5 JP 2015501784A5
Authority
JP
Japan
Prior art keywords
alkyl
disease
methyl
cycloalkyl
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014540115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501784A (ja
JP6005753B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/063235 external-priority patent/WO2013067296A1/en
Publication of JP2015501784A publication Critical patent/JP2015501784A/ja
Publication of JP2015501784A5 publication Critical patent/JP2015501784A5/ja
Application granted granted Critical
Publication of JP6005753B2 publication Critical patent/JP6005753B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014540115A 2011-11-04 2012-11-02 治療の方法 Expired - Fee Related JP6005753B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555650P 2011-11-04 2011-11-04
US61/555,650 2011-11-04
PCT/US2012/063235 WO2013067296A1 (en) 2011-11-04 2012-11-02 Method of treatment

Publications (3)

Publication Number Publication Date
JP2015501784A JP2015501784A (ja) 2015-01-19
JP2015501784A5 true JP2015501784A5 (enExample) 2015-12-24
JP6005753B2 JP6005753B2 (ja) 2016-10-12

Family

ID=48192800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540115A Expired - Fee Related JP6005753B2 (ja) 2011-11-04 2012-11-02 治療の方法

Country Status (11)

Country Link
US (2) US9242962B2 (enExample)
EP (1) EP2773754B1 (enExample)
JP (1) JP6005753B2 (enExample)
KR (1) KR20140095073A (enExample)
CN (1) CN104039956A (enExample)
AU (1) AU2012332297B2 (enExample)
BR (1) BR112014010803A2 (enExample)
CA (1) CA2854447A1 (enExample)
ES (1) ES2600161T3 (enExample)
RU (1) RU2621148C2 (enExample)
WO (1) WO2013067296A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2013361079B2 (en) * 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US9822103B2 (en) 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015120372A2 (en) * 2014-02-10 2015-08-13 University Of Rochester Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
CN106255693A (zh) * 2014-03-07 2016-12-21 葛兰素史密斯克莱知识产权(第2 号)有限公司 Zeste增强子同源物2的抑制剂
SMT202000123T1 (it) 2014-03-17 2020-05-08 Daiichi Sankyo Co Ltd Derivati 1,3-benzodiossolici come inibitori di ezh1 e/o di ezh2
CN107148419A (zh) * 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权(第2 号)有限公司 Zeste增强子同源物2抑制剂
JP2017533922A (ja) * 2014-11-06 2017-11-16 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 移植片対宿主病(gvhd)のためのクロマチン構造を調節する組成物の使用
WO2016073956A1 (en) * 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
JP2018522045A (ja) * 2015-08-03 2018-08-09 コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. Ezh2阻害剤および制御性t細胞機能の調節
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
CN105541801B (zh) * 2016-01-18 2018-07-17 常州大学 Ezh2甲基转移酶抑制剂gsk126的合成方法
EP3445365A4 (en) 2016-04-22 2019-10-16 Dana-Farber Cancer Institute, Inc. EZH2 INHIBITORS AND USES THEREOF
US10676479B2 (en) * 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
AU2017323112B2 (en) * 2016-09-07 2020-11-26 Haihe Biopharma Co., Ltd. Pyrido five-element aromatic ring compound, preparation method therefor and use thereof
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018137639A1 (zh) * 2017-01-25 2018-08-02 恩瑞生物医药科技(上海)有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのprc2サブユニットの阻害
TWI837231B (zh) 2018-11-29 2024-04-01 日商第一三共股份有限公司 含有ezh1/2雙重抑制劑之醫藥組合及其用途
US20220016111A1 (en) * 2018-12-21 2022-01-20 The Walter And Eliza Hall Institute Of Medical Research Methods of Treating Inflammation
CN109761960B (zh) * 2019-02-25 2021-08-31 江苏豪森药业集团有限公司 抗耐药抗肿瘤egfr抑制剂的制备方法
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
US11535621B2 (en) * 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
MX2022007936A (es) 2019-12-25 2022-10-27 Nippon Shinyaku Co Ltd Agente profilactico y/o terapeutico para la prostatitis cronica/sindrome de dolor pelvico cronico.
TW202241418A (zh) 2021-01-29 2022-11-01 美商律幫治療股份有限公司 作為cd38之抑制劑的喹啉及氮雜喹啉

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2584713B1 (fr) 1985-07-11 1988-09-09 Roussel Uclaf Nouveaux derives de l'indole carboxamide, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
EP1633740B1 (en) 2003-06-19 2011-11-09 GlaxoSmithKline LLC 5-(acylamino)indazole derivatives as kinase inhibitors
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
AU2005229522A1 (en) * 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd. Indol-1-yl-acetic acid derivatives
WO2007053114A1 (en) * 2005-10-31 2007-05-10 S*Bio Pte Ltd Method of predicting a response to hdac inhibitors
WO2008109534A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2009048958A2 (en) 2007-10-08 2009-04-16 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
CN104557914A (zh) 2008-09-26 2015-04-29 新加坡科技研究局 3-脱氮瓶菌素衍生物
US9107942B2 (en) * 2008-10-31 2015-08-18 University Of Rochester Methods of diagnosing and treating fibrosis
US8642602B2 (en) * 2009-02-04 2014-02-04 University Of Georgia Research Foundation, Inc. Method of inhibiting fibrogenesis and treating fibrotic disease
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US8536179B2 (en) * 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds

Similar Documents

Publication Publication Date Title
JP6215338B2 (ja) キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
EP2549875B1 (en) Soluble guanylate cyclase activators
EP2789615B1 (en) Azaindazoles as Btk kinase modulators and use thereof
AU2014373735B2 (en) Therapeutic inhibitory compounds
US10428044B2 (en) 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
AU2005259894C1 (en) Pyrrolotriazine kinase inhibitors
CA2803842C (en) Nicotinamide derivative or salt thereof as syk-inhibitors
EP2566477B1 (en) Amino-quinolines as kinase inhibitors
CN104254533B (zh) 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
WO2016011390A1 (en) Irak4 inhibiting agents
EP3568390A1 (en) Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof
JP2013528591A5 (enExample)
WO2009027283A1 (en) Triazolopyridine compounds and their use as ask inhibitors
TW200306180A (en) New compounds
AU2005300736B2 (en) Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
MX2015004151A (es) Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8).
WO2013067300A1 (en) Method of treatment
AU2005292152A1 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
JP2009517383A (ja) 新規な3−ビシクロカルボニルアミノピリジン−2−カルボキサミド又は3−ビシクロカルボニルアミノピラジン−2−カルボキサミド
KR20150135794A (ko) 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 phd의 저해제로서의 그의 용도
EP3600312B1 (en) Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
KR20170044204A (ko) 오렉신―1 수용체의 억제제로서의 치료 화합물
AU2014347026A1 (en) Substituted pyridine derivatives useful as GSK-3 inhibitors
MX2010013549A (es) Imidazoles sustituidos con 2-piridilo, como inhibidores de alk4 y/o alk4.
MX2014015691A (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.